Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8+ T cells showed synergistic effects on improved disease-free survival in treatment-naïve CRC patients
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110207 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Abdo Meyiah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Natural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Oman. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoints (ICs) are highly expressed on tumor-infiltrating immune cells (TIICs) in different malignancies, including colorectal cancer (CRC). T cells play crucial roles in shaping CRC, and their presence in the tumor microenvironment (TME) has proven to be one of the best predictors of clinical outcomes. A crucial component of the immune system is cytotoxic CD8+ T cells (CTLs), which play decisive roles in the prognosis of CRC. In this study, we investigated associations of immune checkpoints expressed on tumor-infiltrating CD8+ T cells with disease-free survival (DFS) in 45 naïve-treatment CRC patients. First, we examined the associations of single ICs, and found that CRC patients with higher levels of T-cell immunoglobulin and ITIM-domain (TIGIT), T-cell immunoglobulin and mucin domain-3 (TIM-3) and programmed cell death-1 (PD-1) CD8+ T cells tended to have longer DFS. Interestingly, when PD-1 expression was combined with other ICs, there were more evident and stronger associations between higher levels of PD-1+ with TIGIT+ or PD-1+ with TIM-3+ tumor-infiltrating CD8+ T cells and longer DFS. Our findings for TIGIT were validated in The Cancer Genome Atlas (TCGA) CRC dataset. This study is the first to report on the association of co-expression of PD-1 with TIGIT and PD-1 with TIM-3 in CD8+ T cells and improved DFS in treatment-naïve CRC patients. This work highlights the significance of immune checkpoint expression on tumor-infiltrating CD8+ T cells as critical predictive biomarkers, especially when co-expression of different ICs is considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Natural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Oman.
- Department of Immunology, Mayo Clinic, Scottsdale, AZ 85259, USA.
- School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Department of Pathology, Hamad Medical Corporation, Doha, Qatar.
- Natural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Oman; Department of Biological Sciences and Chemistry, Faculty of Arts and Sciences, University of Nizwa, Nizwa 616, Oman; Biomedical Researc…
Zitieren
APA
Meyiah, A., Mahmoodi Chalbatani, G., Al-Mterin, M. A., Malekraeisi, M. A., Murshed, K., & Elkord, E. (2023). Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8+ T cells showed synergistic effects on improved disease-free survival in treatment-naïve CRC patients. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110207
Vancouver
Meyiah A, Mahmoodi Chalbatani G, Al-Mterin MA, Malekraeisi MA, Murshed K, Elkord E. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8+ T cells showed synergistic effects on improved disease-free survival in treatment-naïve CRC patients. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110207
BibTeX
@article{Meyiah2023,
author = {Meyiah, Abdo and Mahmoodi Chalbatani, Ghanbar and Al-Mterin, Mohamed A and Malekraeisi, Mohammad Amin and Murshed, Khaled and Elkord, Eyad},
title = {Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8+ T cells showed synergistic effects on improved disease-free survival in treatment-naïve CRC patients},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110207}
}
EUVIMED